Icatibant: a novel approach to the treatment of angioedema related to the use of angiotensin-converting enzyme inhibitors
| Autor: | Michele Alzetta, Mauro Gallitelli |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Drug
Male medicine.drug_class media_common.quotation_subject Angiotensin-Converting Enzyme Inhibitors Pharmacology Bradykinin chemistry.chemical_compound immune system diseases Icatibant Lisinopril Medicine Humans cardiovascular diseases Angioedema skin and connective tissue diseases Bradykinin Receptor Antagonists media_common Aged biology business.industry Anti-Inflammatory Agents Non-Steroidal food and beverages Angiotensin-converting enzyme General Medicine medicine.disease Receptor antagonist Antiallergic drugs chemistry Hereditary angioedema Emergency Medicine biology.protein Anti allergy medicine.symptom business |
| Zdroj: | The American journal of emergency medicine. 30(8) |
| ISSN: | 1532-8171 |
| Popis: | Angioedema related to the use of angiotensin-converting enzyme inhibitors (AE-ACEi) has, so far, been treated with antiallergic drugs with questionable results. Because angioedema in this setting is likely related to increased levels of bradikinin, we decided to use icatibant, a bradikinin receptor antagonist licensed for use in hereditary angioedema, in a patient with AE-ACEi. In the same patient, the time to resolution of the angioedema during previous attacks was about 2 days when classic antiallergic drug regimens were used; when icatibant was used, this time shortened to 10 hours. Icatibant is a promising drug in the treatment of AE-ACEi. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect